Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Mahlangu J, et al. Among authors: asikanius e. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550. N Engl J Med. 2018. PMID: 30157389 Free article. Clinical Trial.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Oldenburg J, et al. Among authors: asikanius e. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10. N Engl J Med. 2017. PMID: 28691557 Free article. Clinical Trial.
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.
Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Santagostino E, Moore M, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R. Mahlangu J, et al. Among authors: asikanius e. Haemophilia. 2018 Nov;24(6):921-929. doi: 10.1111/hae.13612. Epub 2018 Oct 8. Haemophilia. 2018. PMID: 30295389 Clinical Trial.
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. Oldenburg J, et al. Among authors: asikanius e. Haemophilia. 2019 Jan;25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14. Haemophilia. 2019. PMID: 30427582 Free article. Clinical Trial.
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Mancuso ME, Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R, von Mackensen S. Mahlangu J, et al. Among authors: asikanius e. Haemophilia. 2019 May;25(3):382-391. doi: 10.1111/hae.13731. Epub 2019 Apr 24. Haemophilia. 2019. PMID: 31016855 Free PMC article.
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Reyes A, Révil C, Niggli M, Chebon S, Schlagmüller S, Flacke JP, Zortel M, Paz-Priel I, Asikanius E, Hampton R, Mahajan A, Schmidt E, Edwards SC. Reyes A, et al. Among authors: asikanius e. Curr Med Res Opin. 2019 Dec;35(12):2079-2087. doi: 10.1080/03007995.2019.1649378. Epub 2019 Aug 13. Curr Med Res Opin. 2019. PMID: 31355677
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
Oldenburg J, Shima M, Kruse-Jarres R, Santagostino E, Mahlangu J, Lehle M, Selak Bienz N, Chebon S, Asikanius E, Trask P, Mancuso ME, Jiménez-Yuste V, von Mackensen S, Levy GG. Oldenburg J, et al. Among authors: asikanius e. Pediatr Blood Cancer. 2020 Oct;67(10):e28474. doi: 10.1002/pbc.28474. Epub 2020 Aug 9. Pediatr Blood Cancer. 2020. PMID: 32776489
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Callaghan MU, et al. Among authors: asikanius e. Blood. 2021 Apr 22;137(16):2231-2242. doi: 10.1182/blood.2020009217. Blood. 2021. PMID: 33512413 Free PMC article. Clinical Trial.
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Callaghan MU, Asikanius E, Lehle M, Oldenburg J, Mahlangu J, Uguen M, Chebon S, Kruse-Jarres R, Jiménez-Yuste V, Shima M, Trask P, Kempton CL, Kessler CM, Levy GG, Peyvandi F. Callaghan MU, et al. Among authors: asikanius e. Res Pract Thromb Haemost. 2022 Sep 13;6(6):e12782. doi: 10.1002/rth2.12782. eCollection 2022 Aug. Res Pract Thromb Haemost. 2022. PMID: 36171959 Free PMC article.
18 results